Company ProfilePremium

CJ Cheiljedang Corporation

Company Profile Analysis

Ticker: 097950.KS

ESOMAR 23 Corporate BadgeISO Certifications Badge
CJ Cheiljedang Corporation - Company showcase

Year Founded & Workforce

1953

8,175 Employees

CJ Cheiljedang Corporation logo

CJ Cheiljedang Corporation Employee Contacts

71 verified contactsNames, job titles, seniority and locations

View Employee Contacts

CJ Cheiljedang Corporation Overview

CJ CheilJedang is South Korea's largest food company. It is the flagship operating unit of CJ Group, and through a 40.16% stake it consolidates CJ Logistics, Korea's largest logistics company. Its core is a branded processed-food franchise built around bibigo, Hetbahn, Beksul and Dasida. Since the 2019 acquisition of US frozen-food maker Schwan's, that franchise has become a global K-food platform. In FY2025 overseas food sales (KRW 5.92tn) exceeded domestic food sales for the first time. The second pillar is a scale biotechnology business: fermentation-derived amino acids (lysine, tryptophan, valine, arginine and others), nucleotides and specialty ingredients. The company has historically been the world's largest amino acid producer. The company is now in its most significant restructuring since the 2007 spin-off. It divested CJ Feed&Care, abandoned a planned sale of the bio business, and on 1 July 2026 reorganized into three divisions (Lifestyle Food, Technology Materials, Core Materials). It is also contending with record antitrust fines, compressed bio margins and elevated leverage.


What the company does

CJ CheilJedang operates three business families, plus one consolidated subsidiary group:

  1. Food (now "Lifestyle Food")

    • Branded processed foods: frozen dumplings (mandu), instant/processed rice, kimchi, seaweed snacks, sauces and pastes, chicken, frozen pizza, desserts, Asian appetizers, and beverages including fruit vinegar.

    • Domestic "food ingredients" businesses: sugar, flour, edible oils, starch sweeteners and premixes. Under the July 2026 reorganization these sit in Core Materials.

    • Operates globally. North America runs through CJ Foods America / CJ Schwan's, and there are platforms in Japan, China, Vietnam, Europe and Oceania.

  2. Bio (now split into "Technology Materials" and "Core Materials")

    • Fermentation-based "green bio" products.

    • Feed-grade amino acids: lysine, threonine, tryptophan, methionine, valine, arginine, isoleucine, histidine.

    • Food-grade flavour enhancers: nucleotides (IMP/GMP) and the natural seasoning material TasteNrich.

    • New materials: PHA biodegradable plastic and allulose.

    • Per Korean press (KED, Feb 2025), amino acids account for about 90% of bio sales.

  3. Red bio / health (non-core, small)

    • CJ Bioscience (microbiome therapeutics, launched January 2022).

    • Batavia Biosciences (Dutch cell and gene therapy CDMO; 75.8% stake acquired in 2021).

    • CJ Wellcare (health functional foods).

  4. CJ Logistics (consolidated, 40.16% owned)

    • Korea's largest parcel, contract logistics and global forwarding company.

    • By revenue it is the largest consolidated segment: about 43% of Q2 2026 consolidated sales, versus 39% food and 18% bio (Butler.works segment split).

Business and revenue model

DimensionCharacterization
Product vs. service mixPredominantly product sales (processed foods, food ingredients, amino acids). Service revenue comes almost entirely from CJ Logistics. Subscription and licensing revenue is immaterial, although the company licensed lysine strain technology to a Chinese producer in February 2026 (CJ newsroom)
Value-chain positionVertically integrated from commodity processing (raw sugar, wheat, corn, soybean) through fermentation and food manufacturing to branded consumer goods. Logistics adds downstream distribution capability
Customer typesB2C through grocery, convenience, e-commerce (including Coupang, after a 2022–2024 supply dispute was settled) and club stores. B2B covers food service, food manufacturers (sugar, flour, starch syrups), feed compounders and integrators (amino acids), and CPG companies (TasteNrich, nucleotides, PHA)
End-marketsPackaged food (Korea, US, Japan, China, Europe, Oceania); animal nutrition (global swine and poultry); food ingredients; bioplastics; healthcare (marginal)

Company self-description (paraphrased)

Recent IR and recruitment materials describe CJ CheilJedang as a global company that uses distinctive technology and core-materials competitiveness to lead a healthy, enjoyable "lifestyle food" culture and to provide solutions (CJ CheilJedang H2 2026 recruitment notice, September 2026). The FY2025 Sustainability Report, signed by CEO Yoon Seok-hwan, frames the year as one of strategic portfolio reorganization.

Independent characterization

CJ CheilJedang is best understood as three businesses with very different economics sharing one balance sheet:

  • A structurally growing but low-margin global branded-food franchise. FY2025 food operating margin was about 4.6%. It is driven by overseas K-food demand and is held back by a mature, price-regulated domestic market.

  • A highly cyclical, capital-intensive commodity fermentation business. Bio OP fell 36.7% in FY2025 and to KRW 5.5bn in Q1 2026. Its earnings swing with Chinese capacity additions, grain costs and feed-sector demand.

A logistics subsidiary: It inflates consolidated revenue but contributes only 40.16% of its earnings to shareholders.

The company's own strategy now treats branded K-food as the core and the remaining materials businesses as candidates for selective investment, harvest or exit.

Strategy

Stated strategic themes (paraphrased from FY2025–2026 disclosures)

  1. Maximize overseas food growth. Expand into new global markets ("K-food new territory expansion") with GSPs such as dumplings, processed rice and Hetbahn (FY2025 results statement; Q2 2026 statement).

  2. Restructure the bio business and create new demand to restore profitability (FY2025 results statement).

  3. Management efficiency. Cut manufacturing and fixed costs and focus on high-margin products (Q2 2026 statement).

  4. Rebalance the portfolio around three divisions. Divest low-growth, low-margin "marginal businesses" and redeploy resources to future growth (July 2026 reorganization statement).

  5. Become a "global lifestyle leader" (CEO Yoon, as reported in July 2026 coverage).

Initiatives register (last 24 months)

DateInitiativeDetailStatus
Nov 2024Hungary plantAbout KRW 100bn; bibigo dumplings for Europe; chicken line laterOpening scheduled 2H 2026 (n/v whether started)
Nov 2024Sioux Falls plantMore than KRW 700bn; dumplings and egg rollsCompletion 2027
2,025Japan Chiba plantAbout KRW 100bnOperating since Sep 2025
Nov 2024–Apr 2025Bio business sale (about KRW 6tn)Morgan Stanley processCancelled 30 Apr 2025
Oct 2025–Mar 2026CJ Feed&Care divestmentEV about KRW 1tn to Royal De HeusClosed
Feb 2026Lysine strain patent collaboration with Chinese producer XinghuipinTechnology monetizationAnnounced
Feb 2026Cost-linked pricing system for sugar; withdrawal from the Korea Sugar Manufacturers Association; staff barred from contact with competitorsAntitrust remediationImplemented (company statements via Bizhankook)
Feb 2026Price cuts on starch sugar and flourResponse to government price-stabilization pushImplemented
Mar 2026Future Innovation Office under the CEOStructural reformEstablished
Mar 2026PHA supply to Conspec (India)Bioplastics commercializationAnnounced
Mar 2026Automated kimbap production facilityManufacturing technologyBuilt
Jul 2026Three-division reorganizationLifestyle Food / Technology Materials / Core MaterialsEffective 1 Jul 2026
Jul 2026Non-core asset monetizationAbout KRW 230bn of plants; sale-leasebackUnder review
Jul 2026Starch-sweetener divestmentAbout KRW 300bn; carve-out sale to financial investorsUnder review ("nothing finalized")
Jul–Sep 2026Premium spirits (jari)US fine-dining launchLaunched
OngoingRenewable energy (solar, long-term PPAs); Net Zero & Zero Waste 2050ESGSee Section 20

Guidance and targets

ItemGuidanceSource
FY2025 (issued Feb 2025)Low-single-digit consolidated sales growthHanwha Securities, Feb 2025
Q4 2025 (issued Nov 2025)Sales up low single digits YoYKiwoom, Nov 2025
Q3 2026 (issued Aug 2026)Consolidated sales up low double digits YoY; operating margin in the mid-to-high 4% range. Bio profitability to recover YoY but may dip QoQ on oil pricesQuartr Q2 2026 summary
Medium-term financial targets (3–5 years)n/d. No quantified medium-term plan was found in public sources reviewed—
Shareholder returnQuarterly dividends since 2022. The 2022 policy was a payout of at least 20% of separate net income excluding one-offs. KRW 1,500 quarterly payments in 2025–2026Dealsite, May 2023; dividend calendars

Products & Services

Pricing is not publicly disclosed for any product line. CJ sells at list/negotiated wholesale prices to retail and B2B customers. The KFTC has ordered CJ to report sugar price changes and has issued price-reset orders in flour.

Lifestyle Food — global strategic products (GSP)

Brand / productDescriptionTarget customerLaunch / latestNotes and flagships
bibigo Mandu (dumplings)Frozen Korean dumplings in multiple formats, including mini wontons and steamed dumplings; whole-shrimp dumplings are a domestic "mega-hit" being exportedRetail (US, Europe, Japan, China, Oceania), food servicebibigo brand launched 2010 (n/v); Japan Chiba plant from Sep 2025; Hungary plant scheduled 2H 202642% share of the US B2C dumpling market (CJ press release, Nov 2024). US dumpling sales +31% in Q2 2026 (Hanwha/StockHub)
Hetbahn / processed rice / frozen riceShelf-stable cooked rice (Hetbahn) and frozen fried rice; ambient processed rice is a key US growth lineKorean and global retailHetbahn 1996 (n/v this cycle)North American ambient processed rice +39% in Q1 2025 (Dealsite)
bibigo ChickenKorean fried chicken (e.g., "Sobaba Chicken")RetailHungary chicken line planned as a phase-2 expansion—
bibigo KimchiPackaged kimchi; Australian OEM productionRetail—GSP category
bibigo Gim (seaweed)Seaweed snacksRetail—GSP category
K-Sauce / Gochujang (Haechandle), kimchi cooking sauceFermented pastes and all-purpose saucesRetail, food serviceAll-purpose kimchi cooking sauce launched for the global market (CJ Newsroom, Sep 2025)—
Noodles / kimchi ramenbibigo noodle and ramen productsRetail—Sampled at KCON LA 2026
Frozen kimbapSeaweed rice rolls; first overseas launch in Japan (2023); 2.5m units sold in Japan by 2024RetailIndustry-first automated kimbap production facility (CJ press release, 25 Mar 2026)—
Mi-choFruit vinegar drinkRetail (Korea, Japan)—Japan sales +37% in Q2 2025 driven by Mi-cho and dumplings
jariPremium Korean distilled spirit (three SKUs)Korean fine-dining channel in the USUnveiled Jul 2026; New York launch Sep 2026New category entry; positioned as "lifestyle" extension
Cuisine KKorean culinary brand/education platform (cooking classes in LA and New York)Consumers, brand buildingApr 2026Marketing platform

Lifestyle Food — North America (CJ Foods America / CJ Schwan's)

BrandCategoryNotes
Red Baron, Tony's, FreschettaFrozen pizzaPizza +10% in Q1 2025 North America (Dealsite). Pizza weakness flagged in 2Q26 previews (DS Securities)
Mrs. Smith's, EdwardsFrozen pies and dessertsA US pie plant was idled by a tornado in Q1 2025, raising fixed-cost burden (Dealsite, May 2025)
Pagoda, Minh, KahikiAsian-style egg rolls, appetizers, entréesCJ Schwan's describes itself as the leading US producer of Asian-style snacks and appetizers (CJ press release, Nov 2024)
Food service (Schwan's Food Service)Pizza, dessert, Asian appetizers for schools and food serviceSioux Falls plant (2027) to make steamed dumplings and egg rolls for food service

Domestic consumer brands (Korea)

BrandCategoryNotes
BeksulSugar, flour, cooking oil, premixes, syrupsConsumer and B2B ingredient brand
DasidaBeef-stock and seasoning powdersHeritage flavour brand (1975, n/v)
Spam (Korea)Canned luncheon meat under licenceHoliday gift sets drive Q1/Q4 seasonality
GourmetFrozen HMR—
CJ Wellcare (subsidiary)Health functional foods: Bio-Core 50bn probiotics, Jeonripso prostate supplement (Apr 2026), Innerb PDRN (oral), health gummies (7 SKUs, Apr 2026)CJ press releases, Mar–Apr 2026

Core Materials (from Jul 2026)

ProductDescriptionNotes
LysineFeed-grade essential amino acid for swine/poultry; CJ's largest-volume bio productExposed to Chinese capacity; the EU anti-dumping rate on Chinese lysine was set lower than expected (Hana, Sep 2025)
TryptophanHigh-margin feed amino acidIntensifying competition cut Q1–Q2 2026 profitability (Herald Corp, Aug 2026)
Threonine, methionineFeed amino acids; methionine produced in Malaysia (n/v this cycle)Strong methionine sales cited in 2Q26 preview (DS Securities)
SugarRefined sugar (Beksul)Subject to KFTC fine and price-reporting order
FlourMilled wheat flourTop-3 Korean miller; subject to KFTC fine
Edible oilsSoybean and other oils (Incheon 3 plant)Incheon 3 flagged as a non-core asset for sale-leaseback
Starch sweetenersCorn starch, corn syrup, glucose, fructose for beverage, confectionery and bakery customersSale under review; CJ is 4th in the Korean market with a low-10% share
Oligosaccharides, premixesProcessed ingredients—
AlluloseRare low-calorie sugar"New material" within Core Materials
CJ Selecta (66%)Brazilian soy-protein concentrate for feed, chemical and pharma usesSale cancelled in April 2025; retained

Technology Materials (from Jul 2026)

ProductDescriptionNotes
Nucleotides (IMP/GMP)Flavour enhancers for food manufacturersCompetition intensified in 2025
TasteNrich (TnR)Natural fermentation-based seasoning/flavour material for premium taste and sodium reductionQ3 2024 sales +35%; new customers in 2025, though margin was diluted by higher production cost
Specialty amino acidsValine, arginine, isoleucine, histidine, citrulline, cysteineSpecialty share of bio sales reached a record 21% in FY2024 and 22% in Q3 2024 (Dealsite; Youth Daily)
PHA (polyhydroxyalkanoate)Marine-degradable bioplastic, including amorphous PHA gradesSupply deal with Indian compounder Conspec (CJ press release, 30 Mar 2026); commercialized across several industries per FY2025 SR

Red bio (non-core)

EntityActivityStatus
CJ BioscienceMicrobiome-based drug discovery and analysis platform; pipeline n/v this cycle; skin–gut research MOU with a dermatology clinic (Mar 2026)Small; strategic fit questioned under the new structure
Batavia BiosciencesViral-vector and vaccine process development and GMP manufacturing (Leiden, Netherlands)Korean press reported in April 2026 that Batavia was struggling to normalize operations (CB Insights news digest)

Financial Narrative

Income statement — consolidated (incl. CJ Logistics), as originally reported

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products

Food

Domestic processed food, domestic food ingredients (sugar, flour, oil, starch syrups), overseas food (CJ Foods America/Schwan's, Japan, China, Vietnam, Europe, Oceania)

bibigo, Hetbahn, Beksul, Dasida, Gourmet, Spam (Korea), Red Baron, Tony's, Mrs. Smith's

Bio

Feed amino acids, food-grade nucleotides, TasteNrich, specialty amino acids, CJ Selecta soy protein, PHA, allulose

Lysine, threonine, tryptophan, methionine, valine, arginine, isoleucine, histidine, citrulline

CJ Feed&Care (until divestment)

Compound feed, livestock and fresh meat in Korea, Vietnam, Indonesia, Philippines, Cambodia, China and Myanmar

Swine/poultry feed; livestock

CJ Logistics (40.16%)

Parcel (O-NE brand), contract logistics, global forwarding

—

Division Overview

DivisionScopeHeadSource

Lifestyle Food

Global K-food centre: global strategic products (GSP) such as bibigo dumplings, chicken, processed rice, sauces and kimchi, plus domestic consumer foods

Gregory Yep (food division head since 2025; more than 30 years in global food/nutrition R&D and innovation)

Herald Corp, 1 Jul 2026

Technology Materials

High-value R&D-led materials: nucleotides, TasteNrich, PHA biodegradable plastic; solutions-based B2B

CEO Yoon Seok-hwan (concurrent)

Nocut News, Jul 2026

Core Materials

Feed amino acids (lysine, tryptophan), general ingredients (sugar, flour, edible oil), processed materials (oligosaccharides, premixes), new materials (allulose)

Kim Chan-ho, Head of Strategic Support (concurrent)

Herald Corp; Edaily, Jul 2026

CJ Logistics

Unchanged; consolidated subsidiary

Shin Young-soo (CJ Logistics CEO)

CJ Newsroom

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

Food (total)

11,26311,35311,522

of which Overseas food

5,3885,5815,925

of which Domestic food

5,8775,7725,597

Bio

4,1354,2103,959

CJ Feed&Care

2,4932,3090

Total ex-logistics

17,89117,87117,755

Revenue by Segment

Segment OP (KRW Bn)FY2023FY2024FY2025

Food

655620526

Bio

251338203

CJ Feed&Care

-867590

Total ex-logistics OP

8191,032861

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2023FY2024FY2025

Food OP margin

5.85.54.6

Bio OP margin

6.18.05.1

Food revenue YoY growth

1.40.81.5

Bio revenue YoY growth

-14.81.8-5.4

Overseas food share of food revenue

47.849.251.4

Segment Revenue

ItemQ1 2025Q2 2025Q3 2025Q1 2026Q2 2026

Food revenue

2,924.62,687.32,984.0

≈3,000 (Kyobo)

2,844.1

Food OP

128.690.1168.5

≈143 (Kyobo)

70.9

Overseas food revenue

1,488.11,368.81,455.4

+4.5% YoY (Hana)

+10.1% YoY

Domestic food revenue

n/v

1,318.51,528.6

+9% YoY processed (Hana)

+1.4% YoY

Bio revenue

895.41,079.8979.4

≈1,000 (Kyobo)

1,350.9

Bio OP

82.5102.422.05.591.0

F&C revenue

542.5555.3569.2

divested

divested

Income Statement

Metric (KRW Bn, consolidated)FY2021FY2022FY2023FY2024FY2025

Revenue

26,289.230,079.529,023.529,359.127,342.6

Operating income

1,524.41,664.71,291.61,553.01,233.6

Net income (incl. minorities)

892.4802.7559.5361.8-417.0

Income Statement — Revenue

Metric (KRW Bn, ex-logistics)FY2021FY2022FY2023FY2024FY2025

Revenue

15,744.418,779.417,890.517,871.017,754.9

Operating income

1,178.71,268.2819.41,032.3861.2

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Consolidated operating margin

5.805.534.455.294.51

Consolidated net margin

3.392.671.931.23-1.53

Ex-logistics operating margin

7.496.754.585.784.85

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025Source / note

Gross profit

n/v

n/v

n/v

n/v

n/v

—

EBITDA (KRW Bn)

n/v

n/v

2,834

3,095 (orig.) / 2,470 (restated)

2,251

Hanwha (Aug 2025); Kiwoom (Apr 2026). Definitions differ

Pre-tax income (KRW Bn)

n/v

n/v

n/v

610.5 (orig.) / 573.5 (restated)

64.9

Kiwoom

Attributable net income (KRW Bn)

612.9

n/v

386

148 (orig.) / 132.3 (restated)

-571.5

Hana (2022); Hanwha; Kiwoom

EPS, basic (KRW)

n/v

n/v

25,147

9,310 (orig.) / 8,074 (restated)

-34,884

Hanwha; Kiwoom

DPS, common (KRW)

5,0005,500

n/v

n/v

≈6,000

Newsis, Feb 2023 (FY2022 = 1,000×3 + 2,500 final, +500 YoY). FY2025 inferred from quarterly KRW 1,500 payments (record dates Aug 2025, Nov 2025, Feb 2026) and an aggregator yield of 3.16% at KRW 189,600

Financial Analysis

ItemValueDate / source

Total assets

KRW 29.74tn

FY2025 (Wikipedia business-data infobox)

Total equity

KRW 11.55tn

FY2025 (same)

Net debt

KRW 9.49tn (FY2023); KRW 10.12tn (FY2024)

Hanwha Securities, Aug 2025

Net debt / EBITDA

3.7x (end-2024) → 4.3x (Sep 2025)

NICE Ratings via Dealsite, Apr 2026

EBITDA / sales

10.9% (end-2024) → 10.2% (Sep 2025)

NICE Ratings via Dealsite

Debt / equity

167.8% (TTM)

TipRanks, mid-2026

Current ratio

0.81 (TTM)

TipRanks, mid-2026

Book value per share

KRW 447,258 (FY2025E)

Kiwoom, Apr 2026

Inventories

Up about KRW 666.7bn (~30%) after forward purchases of soybeans

Half-year report, per MyDailyByte news digest, Sep 2026

Cash & equivalents; short/long-term debt split; goodwill & intangibles; working capital

n/v

—

Financial Analysis (2)

ItemStatus

Operating cash flow, capex, free cash flow, dividends paid, buybacks (5-year)

n/v. TipRanks TTM ratios (price/FCF 9.2x; price/OCF 1.9x; mid-2026) imply TTM OCF of roughly KRW 1.5tn and FCF of roughly KRW 0.3tn at a KRW 2.9tn market cap. These are derived and approximate

Dividends paid (FY2022)

KRW 88.1bn in total (quarterly + final)

Buybacks

No new buyback authorization found; treasury stock 2.37–2.4%

Committed growth capex

Hungary about KRW 100bn (EUR 75–80m); Sioux Falls more than KRW 700bn (completion 2027); Japan Chiba about KRW 100bn (done)

Financial Analysis — ROE

RatioValueSource / date

ROE

5.6% (FY2023); 2.0% (FY2024); 3.1% (FY2025E, pre-impairment estimate); negative actual FY2025

Hanwha, Aug 2025

ROA, ROIC, interest coverage, asset turnover, cash conversion cycle

n/v

—

P/B

0.42x

Butler.works, Oct 2026

EV/EBITDA (TTM)

5.0x

TipRanks, mid-2026

Q2 2025 by Quarter

Quarter (KRW Bn)Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

7,237.27,439.55,457.47,111.17,362.1

Operating income

353.1346.5204.8238.1257.5

Net income

209.1119.2-798.7119.8-3.8

Revenue by Region

Region (KRW Bn)FY2023FY2024FY2025

Domestic food (Korea)

5,8775,7725,597

Overseas food (all regions)

5,3885,5815,925

Region Overview

RegionLatest disclosed dataSource

North America

FY2024 revenue KRW 4,713.8bn. Q1 2025 KRW 1,247.0bn; Q2 2025 KRW 1,112.0bn. Q3 2025 +3%; Q1 2026 +3.5% in KRW (about +2% in USD); Q2 2026 +10.1% in KRW (+4% in USD). The US accounted for more than 80% of overseas food sales in 2024

Dealsite; Korea Times; Hana/StockHub

Europe

Annual sales exceeded KRW 100bn for the first time in FY2024. Q1 2025 +36%; Q3 2025 +13%; Q1 2026 +17%; Q2 2026 double-digit. Present in 27 European countries by end-Q3 2025

Dealsite; CJ Newsroom; Hana

Japan

Q2 2025 +37% (Mi-cho, dumplings). Chiba plant from Sep 2025. Q3 2025 +4%. Q1 2026 −2% (Kyobo)

Dealsite; Kyobo

China

Q1 2025 +15%+. Q2 2026 +5% on mandu and frozen rice balls

Dealsite; Herald Corp

Oceania / APAC

Q1 2025 Oceania +25%; Q3 2025 +5%; Q1 2026 APAC +17%. Bibigo ranged in about 80% of stores of major Australian retailers (FY2024)

Dealsite; Hana

Latin America

Market-entry stage (bibigo pavilion at a Mexico K-expo, late Sep 2026)

MyDailyByte digest

Point Details

PointPrice (KRW)Source

13 Oct 2020 (reference)

398,000

Asia Economy

10 Feb 2025

250,000

Hanwha

11 Aug 2025

250,000

Hanwha

11 Nov 2025

229,000

Kiwoom

31 Mar 2026

216,500

Kiwoom

6 Aug 2026

201,500

Investing.com

30 Sep 2026

178,900

MyDailyByte

Oct 2026 (latest available)

189,600

Butler.works

52-week range (mid-2026)

172,600 – 254,000

TipRanks

Capital Markets Data

Market cap (KRW Bn)Feb 2025Aug 2025Nov 2025Mar 2026Oct 2026

CJ CheilJedang

3,763.53,763.53,447.43,259.22,854.3

Valuation Multiples

MultipleCJ CheilJedangSource

P/E (trailing)

Not meaningful (FY2025 loss)

Butler.works

Forward P/E

10.5x

Butler.works, Oct 2026

P/E FY2026E (Kiwoom)

9.7x at KRW 216,500

Kiwoom, Apr 2026

P/B

0.42x

Butler.works

EV/EBITDA (TTM)

5.0x

TipRanks

EV/Sales

n/v

—

Peer multiples

n/v. Samyang Foods market cap about KRW 9.6–9.8tn, roughly 3.4x CJ's on about 13% of CJ's ex-logistics revenue

Yuanta, Apr–May 2026

Analyst Ratings & Targets

BrokerDateRatingTarget (KRW)

Consensus (12 brokers)

Oct 2026

—273,333

Kiwoom

1 Apr 2026

Buy

310,000

DS Investment & Securities

2 Jul 2026

Buy

300,000

Shinhan

10 Jul 2026

Buy

280,000

Yuanta

21 Jul 2026

Buy

260,000

Hana

Aug 2026

Buy

370,000 (per StockHub summary; may be stale)

DPS, common (KRW)

DPS, common (KRW)FY2021FY2022FY2025

Dividend per share

5,0005,5006,000

Analyst Conclusions

Management guidance

Q3 2026: consolidated sales up low double digits YoY; operating margin in the mid-to-high 4% range.

Bio: YoY recovery expected, with possible QoQ dilution from oil prices.

Strategy: premiumization, global expansion and innovation in Foods and Bio.

Portfolio: continued disposal of non-core assets.

Consensus expectations (Kiwoom, Apr 2026)

Metric (KRW Bn, consolidated)FY2025AFY2026EFY2027E
Revenue27,342.628,503.229,415.7
Operating profit1,233.61,323.61,491.2
Net income-417.0601.7736.3

H1 2026 actual OP was KRW 495.7bn (−17.9% YoY). This implies a heavy 2H weighting is needed to reach the FY2026E figure; the risk of further downward revisions is material.

Bull case

  1. Deep value with a visible catalyst path. The stock trades at 0.42x book. Asset sales (F&C closed; starch and plants pending) and a bio upcycle could lift ROE from negative toward the 5–6% levels of FY2023.

  2. Bio has troughed. Bio OP recovered from KRW 5.5bn (Q1 2026) to KRW 91bn (Q2 2026) on revenue +20.8%. Multiple brokers expect 2H normalization, helped by grain and oil-driven pricing.

  3. The global food engine is intact and gaining capacity. Overseas food is now more than 50% of food sales. Europe and APAC are growing at double digits, and Hungary (2026) and Sioux Falls (2027) add localized capacity in under-penetrated markets.

Bear case

  1. Structural margin erosion in staples. Two record antitrust fines, price-reset orders and political scrutiny cap pricing in sugar, flour and starch. Domestic food is shrinking.

  2. Chinese competition makes bio a lower-quality earnings stream. FY2025 bio OP fell 36.7%, and tryptophan and specialty premiums are being competed away. The failed KRW 6tn sale suggests the market values the asset below management's view.

  3. Balance-sheet and governance overhang. Net debt/EBITDA was 4.3x with NICE triggers in sight; impairments drove a FY2025 net loss; and minority holders face controlling-shareholder priorities and a logistics stake that dilutes the investment case.

Key catalysts and monitorables (next 12 months)

  1. Q3 2026 results (about 8–11 Nov 2026): delivery against the low-double-digit sales and mid-to-high 4% margin guidance.

  2. First production at the Hungary plant and early European margin data.

  3. Outcome of the starch-sweetener and plant sale-leaseback processes, and any further divestments (e.g., Selecta, red bio).

  4. The KFTC starch-syrup sanction and any criminal proceedings.

  5. NICE and other domestic rating reviews (EBITDA/sales and net debt/EBITDA).

  6. Amino acid price trends, especially lysine and tryptophan, and Chinese capacity additions.

  7. First restated segment history under the three-division structure.

  8. Sioux Falls construction progress toward 2027 commissioning.

Concluding analyst verdict

CJ CheilJedang enters late 2026 as a company whose franchise value and financial performance have diverged sharply. On the franchise side, the evidence is unambiguous. It owns the most successful global Korean-food brand, bibigo, with leadership in the world's largest consumer market (42% of US B2C dumplings). Overseas food has become the majority of its food revenue, and it is investing in localized capacity in Europe and the US Midwest. Its fermentation technology remains globally relevant, as shown by its ability to license strain IP into China itself.

The financial record tells a different story:

  • Consolidated operating profit has fallen from KRW 1.66tn (FY2022) to KRW 1.23tn (FY2025).

  • Net income has fallen from KRW 892bn (FY2021) to a KRW 417bn loss.

  • Leverage has crept toward rating triggers.

  • Two consecutive record antitrust fines have damaged the legitimacy of its domestic staples business.

The July 2026 three-division reorganization is the right diagnosis. It concentrates capital on Lifestyle Food, ring-fences high-value Technology Materials, and puts commodity Core Materials on a cash and synergy mandate with explicit permission to exit marginal units. The question is execution: the 2025 failures to sell the bio business and Selecta show how hard that is.

At about 0.4x book and roughly 10x forward earnings, the market is pricing persistent value destruction. Even modest progress could re-rate the shares: a sustained bio recovery, a completed starch sale and a clean Hungary ramp-up. The 2026 interim numbers (H1 OP −17.9%) do not yet show that progress. On balance the shares screen as deep value with elevated execution and regulatory risk. The risk/reward improves materially once two conditions are met:

  • Q3/Q4 2026 confirm bio normalization.

  • Divestment proceeds visibly reduce net debt below about 4x EBITDA.

Until then, the investment case rests more on asset value than on earnings momentum.


Source notes

Primary and near-primary sources used:

  • CJ CheilJedang IR and press releases (cj.co.kr; CJ Newsroom).

  • DART preliminary results (via StockHub summaries).

  • Company sustainability reports.

Press and research sources used:

  • Korean and international press: Korea Herald, Korea JoongAng Daily, KED Global, Korea Times, Dealsite, Edaily, Herald Corp, Asia Economy, Digital Today, Nocut News, Financial News.

  • Broker research excerpts: Kiwoom, Hanwha, Hana, IBK, iM, Yuanta, DS, Shinhan, Kyobo.

  • Data aggregators (TipRanks, Simply Wall St, Butler.works, Investing.com, TheVC, Quartr) are used only where primary data were unavailable, and are flagged.

Figures should be reconciled to the FY2025 audited business report and the Q2 2026 half-year report on DART before external use.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundSource

Sohn Kyung-shik

Chairman and Representative Director

Long-standing (also CJ Group Chairman)

n/v this cycle

Corporate registry summary

Yoon Seok-hwan

CEO and Representative Director; concurrently head of Technology Materials

CEO since Oct 2025

Formerly CEO of the Bio business unit; previously led South American bio operations, global bio marketing and the biotech research centre

Korea JoongAng Daily; Simply Wall St

Gregory Yep

Head, Lifestyle Food Division

Food division head since 2025

More than 30 years in R&D and business innovation at global food and nutrition companies

Herald Corp, Jul 2026

Kim Chan-ho

Head, Strategic Support Division; concurrently head of Core Materials

Since 2026 reorganization

Former CEO of CJ Foodville

KED Global, Feb 2024; Edaily, Jul 2026

Kyoung-suk Kang

Head, Finance Strategy Office

n/v

n/v

Simply Wall St

Shin Young-soo

CEO, CJ Logistics (subsidiary)

Since Feb 2024

Launched the O-NE delivery brand

KED Global

Board & Management Changes

DateChangeContext

Dec 2020

Choi Eun-seok CEO; Kang Sin-ho moves to CJ Logistics

Group reshuffle

Mar 2022

Pak Min-sok (ex-Mondelez global chief strategist) hired as Chief Growth Officer; later CEO of CJ Foods

Growth/GSP agenda

Feb 2024

Kang Sin-ho returns as CEO and Vice Chairman

After FY2023 net profit fell nearly a third

Oct 2025

Yoon Seok-hwan replaces Kang (health reasons)

CEO appointments made ahead of the regular reshuffle

1 Jul 2026

Three-division leadership: Yep, Yoon (concurrent), Kim (concurrent)

Portfolio restructuring

Major Shareholders

HolderStakeDate / source

CJ Corp. and related parties

45.5%

Kiwoom, Apr 2026

National Pension Service

10.0% (down from 12.5% in Feb 2025)

Hanwha, Aug 2025 / Feb 2025

Treasury stock

2.37–2.4%

Butler.works; Hanwha

Foreign investors (aggregate)

15.2% (Mar 2026), down from 22.6% (Feb 2025)

Kiwoom; Hanwha

Top 10 institutional holders (individual)

n/v

—

Insider ownership (management)

n/v; negligible outside the CJ family / CJ Corp. block

—

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsNotes

Korean processed food

Daesang (Chung Jung One), Ottogi, Nongshim, Samyang Foods, Dongwon F&B, Pulmuone, Lotte Wellfood

CJ is the largest by revenue

Korean sugar

Samyang Corp., Daehan Sugar (TS)

Three-player oligopoly fined in 2026

Korean flour

Daehan Flour Mills, Sajo DongA One, Samyang Corp., Daesun, Samhwa, Hantop

Top 3 (Daehan, Sajo DongA One, CJ) hold more than 70% of a KRW 1.3tn market

Korean starch sweeteners

Daesang, Sajo CPK, Samyang

Four firms hold more than 90%; CJ ranks 4th with a low-10% share

US Asian frozen food / dumplings

Ajinomoto Foods North America (Ling Ling), private label, other Asian-food brands

bibigo holds 42% of US B2C dumplings and leads the No. 2 brand by more than 3x (Dealsite, Feb 2025)

US frozen pizza

Nestlé (DiGiorno), Conagra, private label

Red Baron/Tony's compete in mainstream frozen pizza

K-food exports (noodles)

Samyang Foods (Buldak), Nongshim (Shin Ramyun)

Faster-growing, higher-margin K-food exporters

Feed amino acids

Meihua, Fufeng, Eppen (China), Ajinomoto, ADM, Evonik (methionine), Novus

Chinese low-cost capacity is the structural threat

Nucleotides / flavour

Ajinomoto, Chinese producers

Price competition intensified in 2025

Peer Comparison FY2025

MetricCJ CheilJedang (ex-logistics, FY2025)Ajinomoto (FY to Mar-2026)Samyang Foods (FY2025)Ottogi (FY2025)

Revenue

KRW 17.75tn

JPY 1.58tn

about KRW 2.3tn

about KRW 3.6tn

Revenue growth

−0.6%+3.5%

n/v (OP +52% vs FY2024)

n/v

Operating profit

KRW 861bn

Business profit n/v for FY to Mar-2026; FY to Mar-2025: JPY 159.3bn

KRW 524bn

about KRW 177bn

Operating margin

4.9%

about 10.4% (FY to Mar-2025, business profit basis)

about 22.8%

about 4.9%

Net income

−KRW 417bn (consolidated)

JPY 134.7bn

n/v

n/v

R&D intensity

about 1.2% (FY2024)

n/v

KRW 7.9bn R&D (FY2024; Hankyung)

n/v

Company Snapshot

$19,241.8M

Revenue

8,175

Employees

1953

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Overseas food scale. FY2025 overseas food sales of KRW 5.92tn exceeded domestic for the first time (Korea Herald, Feb 2026).
  • US category leadership. bibigo holds 42% of US B2C dumplings (CJ press release, Nov 2024).
  • Brand equity. Interbrand 2026 brand value of KRW 1.1866tn, #1 among Korean FMCG companies and #22 overall.
  • Bio technology leadership. Specialty amino acids reached 21% of bio sales in FY2024; the company is licensing strain IP in China (2026).
  • Capital-market access. The January 2026 KRW 250bn bond was 5.8x oversubscribed at negative spreads; rated AA0 (stable).
  • Diversified production base. 11 bio plants, plus Japan (2025), Hungary (2026) and US (2027) food capacity.

Weaknesses

  • Low profitability. Consolidated OP margin was 4.5% in FY2025, versus about 22.8% at Samyang Foods.
  • Earnings volatility. Net income fell from KRW 892bn (FY2021) to −KRW 417bn (FY2025).
  • Leverage. Net debt was about KRW 10.1tn (FY2024); net debt/EBITDA reached 4.3x by September 2025 (NICE).
  • Weak domestic food. Q4 2025 domestic food fell 3.8% YoY.
  • Failed divestments (bio, Selecta), which undermine portfolio-management credibility (Edaily, Aug 2026).
  • Underperforming red-bio bets. Batavia was reported to be struggling to normalize in April 2026.

Opportunities

  • European expansion, with sub-regions growing 13–36% in 2025–2026 and the Hungary plant from 2H 2026.
  • US food-service dumplings through Sioux Falls (more than KRW 700bn, 2027).
  • Bio cycle recovery. Q2 2026 bio OP of KRW 91bn versus KRW 5.5bn in Q1; brokers expect normalization in 2H 2026.
  • Value release from non-core sales (starch about KRW 300bn; plants about KRW 230bn) to deleverage.
  • New categories: PHA, allulose, TasteNrich, premium spirits (jari), health functional foods.
  • Valuation re-rating potential. P/B is 0.42x against a broker consensus target of about KRW 273,333 (12 brokers).

Threats

  • Antitrust: sugar (KRW 138.3bn) and flour (KRW 131.71bn) fines, a starch-syrup case pending, and prosecution referrals.
  • Chinese amino acid competition. Tryptophan competition drove the 2026 margin compression.
  • Input costs and FX: oil prices, a strong won and raw materials all cited in Q2 2026.
  • Credit-rating downgrade risk against explicit NICE triggers.
  • Political and price-control pressure on staple foods; the President called collusion "cancerous" (JoongAng, Feb 2026).
  • Competition for K-food leadership from Samyang Foods and Nongshim, which grow faster at higher margins.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 May 2025Q1 2025 results: consolidated OP KRW 333.2bn (−11.4%); US pie plant hit by tornado; Europe +36%Food margin pressure begins
14 May 2025KRW 100bn Japan (Chiba) dumpling plant announcedJapan localization
19 May 2025SEVENTEEN named bibigo global ambassadorsBrand push
12 Aug 2025Q2 2025: consolidated OP KRW 353.1bn; domestic food −5%; Japan +37%Domestic weakness persists
Aug 2025Hanwha downgrades to Hold (target KRW 250,000)Sentiment turns
4 Sep 2025Global all-purpose kimchi cooking sauce launchedGSP extension
11 Sep 2025Chiba plant begins operationsCapacity online
30 Sep 2025Hana cuts target to KRW 350,000 on lysine and specialty competition and the EU anti-dumping outcomeBio downcycle signal
1 Oct 2025SPA to sell CJ Feed&Care to Royal De Heus (EV about KRW 1tn)Portfolio simplification; deleveraging
Oct 2025Yoon Seok-hwan named CEO as Kang Sin-ho steps downLeadership change
11 Nov 2025Q3 2025: consolidated OP KRW 346.5bn (−15.9%); bio OP KRW 22bn (−71.9%)Bio trough deepens
12 Nov 2025Kiwoom cuts target to KRW 280,000Estimate cuts
Jan 2026KRW 250bn bond issue, 5.8x oversubscribed; rated AA0 (stable)Market access intact
Jan 2026Food-service flour price cut 4%; prosecutors receive referrals for seven millers and 14 executivesRegulatory pressure
9 Feb 2026FY2025 results: net loss KRW 417bn on non-cash impairments; overseas food > domesticInflection in mix; earnings low
12 Feb 2026KFTC sugar collusion fine (CJ about KRW 150.7bn); public apology; exit from sugar associationLargest-ever per-company collusion fine
22 Feb 2026Lysine strain patent tie-up with Xinghuipin (China)IP monetization
23–26 Feb 2026Starch-sugar and further flour price cutsMargin headwind
Early Mar 2026De Heus completes F&C acquisitionDivestment closed
12 Mar 2026Sugar fine finalized/adjusted to KRW 138.3bnLiability crystallized
Mar 2026Future Innovation Office created; PHA deal with Conspec; automated kimbap facilityRestructuring and innovation
31 Mar 202628th AGM; FY2025 dividend approvedGovernance
Apr 2026NICE Ratings flags downgrade triggers (EBITDA/sales < 10%; net debt/EBITDA > 5x)Credit pressure
14 Apr 2026EGM appoints outside directors and audit committee membersGovernance refresh
12 May 2026Q1 2026: consolidated OP KRW 238.1bn (−28.5%); bio OP KRW 5.5bnBio trough
20 May 2026KFTC flour fine (CJ KRW 131.71bn of KRW 671bn total)Second major antitrust hit
Jun 2026Interbrand: brand value KRW 1.1866tn, #1 FMCGBrand strength
1 Jul 2026Three-division reorganizationStrategic reset
7 Jul 2026Non-core plant sales (about KRW 230bn) reportedAsset monetization
10 Jul 2026Shinhan reiterates Buy (target KRW 280,000), citing 2H bio normalizationSell-side support
20 Jul 2026jari premium spirit unveiledNew category
28 Jul 2026Starch-sweetener unit sale under reviewPortfolio pruning
11 Aug 2026Q2 2026: ex-logistics sales +10.2%, OP −18.4%; bio OP recovers to KRW 91bn; Q3 guidance issuedMixed; bio recovery
14 Aug 2026Half-year report filed; inventories up about 30% on soybean forward buyingWorking-capital build
14–15 Aug 2026CJ Chairman at KCON LA; group calls North America "life-or-death"Group priority on the US
16–30 Sep 2026H2 2026 graduate recruitment; "CJ UNBOUND" AI recruiting conferenceTalent
Sep 2026jari launched in New York; bibigo booth at Mexico K-expoNew markets/categories
Nov 2026 (expected)Q3 2026 results (Investing.com calendar lists 8 Nov 2026)Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement (FY2021–FY2025): Revenue & Operating income: Revenue rose from KRW 15,744.4 Bn in FY2021 to KRW 17,754.9 Bn in FY2025.
CJ Cheiljedang Corporation — Income Statement (FY2021–FY2025): Revenue & Operating income
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue15,744.418,779.417,890.517,87117,754.9
Operating income1,178.71,268.2819.41,032.3861.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.